LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 8, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that presentations related to ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and STA-12-8666, the Company’s leading candidate from its proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be presented at the 16^th Annual World Conference on Lung Cancer at the Colorado Convention Center in Denver, Colorado.

Details of the presentations are provided below:

Mini Oral Presentations:

HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells and Inhibits Lung Cancer Stem Cells

Date and Time: Tuesday, September 8, 10:45 AM - 12:15 PM MT
Location: Mile High Ballroom 2c - 3c, MINI14.08
Presenter: Vera Levina, Ph.D., University of Pittsburgh

The Novel HSP90 Inhibitor-SN-38 Conjugate (STA-12-8666), Is Highly Active in Preclinical Models of Small Cell Lung Cancer (SCLC)

Date and Time: Wednesday, September 9, 6:30 -8:00 PM MT
Location: Rooms 605+607, MINI37.02
Presenter: Yanis Boumber, M.D., Ph.D., University of New Mexico

Poster Presentations:

Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated through Reactivation of the RAF/MEK/ERK and PI3K/MTOR Pathways

Date and Time: Tuesday, September 8, 9:30AM – 5:00 PM MT
Location: Exhibit Hall (Hall B+C), Poster P2.04-101
Presenter: Timothy F. Burns, M.D., University of Pittsburgh

A Phase Ib/II Trial of Doxorubicin with Ganetespib, a Novel Hsp90 Inhibitor, in Advanced Solid Tumors, with Dose Expansion in Small Cell Lung Cancer

Date and Time: Wednesday, September 9, 9:30 AM – 5:00 PM MT
Location: Exhibit Hall (Hall B+C), Poster P3.07-003
Presenter: Deepa Subramaniam, M.D., Georgetown University

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005885/en/

Source: Synta Pharmaceuticals Corp.

Investors:
Synta Pharmaceuticals Corp.
Daniel Cole, 781-541-7250
[email protected]
or
Argot Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot Partners
Eliza Schleifstein, 917-763-8106
[email protected]